| Intrinsic Valuation of: SYNGENE | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 12 | Market Cap | ₹257B | |||||
| 2021 | - | - (-) | P/E Ratio | 52 | Total Asset | ₹68B | |||||
| 2022 | ₹1B | - (-) | Net Income | ₹5B | Total Debt | ₹0 | |||||
| 2023 | ₹3B | 190.4% (136.3%) | EBITDA | ₹11B | Total Liab | ₹21B | |||||
| 2024 | ₹5B | 74.1% (53.7%) | Opr Margin | 0.17 | Debt/Equity | - | |||||
| 2025 | ₹4B | -25.2% (-28.3%) | PreTax Margin | 15.32 | BV/Share | 117 | |||||
| 5Y Average FCF | ₹3B | 79.8% (53.9%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.5% | Historical US Bond Yield: | 4.4% | ||||||||
| Discount Rate (WACC): | 7.4% | Current US Bond Yield: | 3.5% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (25.0%) | ||||||||||
| 2026 | ₹5B | MBG Intrinsic Value | ₹110 | ||||||||
| 2027 | ₹6B | ||||||||||
| 2028 | ₹8B | ||||||||||
| 2029 | ₹10B | ||||||||||
| 2030 | ₹12B | ||||||||||
| 2031 | ₹15B | ||||||||||
| Terminal Value | ₹315B | Net Worth/Share | ₹118 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹247B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹4B | ₹624 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹0 | WACC | 7.3% | 544 | 586 | 638 | 701 | 781 | |||
| Equity Value | ₹251B | 7.4% | 539 | 580 | 631 | 693 | 770 | ||||
| Shares Outstanding | 401,768,000 | 7.4% | 534 | 575 | 624 | 684 | 760 | ||||
| 7.9% | 488 | 522 | 562 | 610 | 669 | ||||||
| DCF Intrinsic Value | ₹624 | 8.4% | 450 | 478 | 511 | 550 | 597 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||